Category Archives: Stem Cell Human Trials

GAITHERSBURG, MD--(Marketwire - Mar 15, 2013) - Cytomedix, Inc. ( OTCQX : CMXI ), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that Edward Field, the Company's Chief Operating Officer, has been invited to make a presentation at the Canaccord Genuity Musculoskeletal Conference, which will be held on Tuesday, March 19, 2013. Presentation Details Time: Tuesday, March 19 at 8:30am CT / 9.30am EDT Room: Huron A Room, Track III Location: Westin Michigan Avenue, 909 North Michigan Avenue, Chicago A live webcast of the presentation may be accessed through the Company's website at http://www.cytomedix.com. A replay of the webcast will be available for one week following the conference. Cytomedix will also be hosting an exhibit at the American Academy of Orthopedic Surgeons (AAOS) annual meeting, which will take place, March 19th - 22nd at the McCormick Place convention center in Chicago. Please visit the Company at booth #4453. About the Canaccord Genuity Musculoskeletal ConferenceThe Canaccord Genuity Musculoskeletal Conference will explore the current state of orthopedics, biologics, imaging, robotic surgery, tissue sculpting, and regenerative tissue companies. This event is expected to have 60 companies present, both public and private. The conference directly precedes … Continue reading →

GAITHERSBURG, MD--(Marketwire - Mar 12, 2013) - Cytomedix, Inc. ( OTCQX : CMXI ) (the "Company"), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that the Company will release financial results for the three- and twelve-months ended December 31, 2012, after the close of the market on Monday, March 18, 2013. Martin Rosendale, Chief Executive Officer, and Andrew Maslan, Chief Financial Officer, will host a conference call beginning at 8:30am Eastern time on Tuesday, March 19, 2012 to discuss the fourth quarter and fiscal year 2012 results and to answer questions. James Hinson, MD, Chief Medical Officer, will join the call to discuss progress made on rolling out Coverage with Evidence Development for AutoloGel. Conference Call & Webcast Tuesday, March 19, 2013 @ 8:30am Eastern/5:30am Pacific Domestic dial in: 866-700-0161 International: 617-213-8832 Passcode: 42664770 Webcast: http://www.cytomedix.com Replays - Available through March 26, 2013 Domestic: 888-286-8010 International: 617-801-6888 Passcode: 23856984 About Cytomedix, Inc. Cytomedix, Inc. is an autologous regenerative therapies company commercializing innovative platelet technologies for orthopedics and wound care with a pipeline of adult stem cell therapies for tissue repair. The Company markets the AutoloGel System, a device for the production of … Continue reading →

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Dr. Michael D. West, Chief Executive Officer, will present a corporate overview of BioTime and its subsidiaries at the 25th Annual ROTH Conference. The presentation will take place on Monday, March 18, 2013 at 5:30 p.m. PDT at The Ritz-Carlton, Laguna Niguel, in Dana Point, California. The presentation will be webcast and available online at the Investors section of the website at http://www.biotimeinc.com and at http://wsw.com/webcast/roth27/btx/. About BioTime, Inc. BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is enhanced through subsidiaries focused on specific fields of application. BioTime develops and markets research products in the fields of stem cells and regenerative medicine, including a wide array of proprietary PureStem cell lines, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (formerly known as HyStem-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases … Continue reading →

Newswise INDIANAPOLIS -- Researchers at the Eugene and Marilyn Glick Eye Institute and the Indiana Center for Vascular Biology at Indiana University School of Medicine are on the cusp of perfecting stem cell treatments that would halt and potentially reverse vision loss caused by diabetic retinopathy. Rajashekhar Gangaraju, Ph.D., assistant professor of ophthalmology and cellular and integrative physiology, Eugene and Marilyn Glick Eye Institute and the Indiana Center for Vascular Biology and Medicine, is the principal investigator in the nearly $2 million study funded by the National Eye Institute, part of the National Institutes of Health. Long interested in the causes and effects of diabetic retinopathy his father and grandfather both suffered from diabetes and resulting vision loss Dr. Gangaraju has focused his research on retinal vascular biology. His research team consists of Keith L. March, M.D., Ph.D., director, Indiana Center for Vascular Biology and Medicine and the Center for Regenerative Medicine, Maria B. Grant, M.D., currently at the University of Florida (and joining the Glick Eye Institute as senior chair in July) and others at the Glick Eye Institute and IU School of Medicine who are conducting complementary research. Dr. Gangaraju said the five years of funding puts researchers … Continue reading →

Quotes are real-time for NASDAQ, NYSE, and NYSEAmex when available. See also delay times for other exchanges. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein. Fundamental company data provided by Capital IQ. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data and daily updates provided by Morningstar, Inc. Yahoo! - ABC News Network Original post: ACT’s Dr. Robert Lanza Voted Top 4 “Most Influential People on Stem Cells” … Continue reading →

SOUTH SAN FRANCISCO, CA--(Marketwire - Mar 12, 2013) - VistaGen Therapeutics, Inc. ( OTCQB : VSTA ), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announces that it will present key enhancements to LiverSafe 3D, its human liver cell-based bioassay system designed to predict liver toxicity and drug metabolism issues, in a poster presentation at the Society of Toxicology's 52nd Annual Meeting, the world's premier toxicology conference,in San Antonio, Texas, onMarch 12, 2013, at 11:00 am PDT. Dr. Kristina Bonham, Senior Scientist, Hepatocyte Biology Project Leader, will present VistaGen's poster titled "Selection of CYP3A4+hESC-derived Hepatocytes for Drug Metabolism and Toxicity Assays," which will detail the following expanded data: H. Ralph Snodgrass, PhD, VistaGen's President and Chief Scientific Officer, stated, "These data demonstrate that we have substantially improved our LiverSafe 3D and now have the potential to identify and purify human hepatocytes with more mature functions, as well as provide a novel assay for drugs that effect CYP3A4 enzyme expression, activity and key drug-drug interactions." Dr. Snodgrass continued, "I am excited by the fact that further improvements in our differentiation protocols have enabled our scientists to produce cultures withmore than80% mature hepatocytes … Continue reading →

Mar. 12, 2013 In laboratory studies, Johns Hopkins researchers say they have found that stem cells from a patient's own fat may have the potential to deliver new treatments directly into the brain after the surgical removal of a glioblastoma, the most common and aggressive form of brain tumor. The investigators say so-called mesenchymal stem cells (MSCs) have an unexplained ability to seek out damaged cells, such as those involved in cancer, and may provide clinicians a new tool for accessing difficult-to-reach parts of the brain where cancer cells can hide and proliferate anew. The researchers say harvesting MSCs from fat is less invasive and less expensive than getting them from bone marrow, a more commonly studied method. Results of the Johns Hopkins proof-of-principle study are described online in the journal PLOS ONE. "The biggest challenge in brain cancer is the migration of cancer cells. Even when we remove the tumor, some of the cells have already slipped away and are causing damage somewhere else," says study leader Alfredo Quinones-Hinojosa, M.D., a professor of neurosurgery, oncology and neuroscience at the Johns Hopkins University School of Medicine. "Building off our findings, we may be able to find a way to arm … Continue reading →

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) today announced it has amended its $5 million Stock and Warrant Purchase Agreement with Romulus Films, Ltd., originally signed on January 4, 2013. Through the amendment, BioTime and Romulus have agreed to accelerate the closing date for the $3 million second tranche of the $5 million financing. The first $2 million tranche under the agreement was funded in January 2013. The second tranche was originally intended to close later this year concurrent with the closing of the acquisition of certain stem cell assets by BioTimes subsidiary BioTime Acquisition Corporation (BAC) pursuant to an Asset Contribution Agreement among BioTime, BAC, and Geron Corporation. Under the amendment, the remaining $3 million investment in BioTime will be funded on April 10, 2013. Romulus has also committed to invest $5 million in BAC in conjunction with the consummation of the stem cell asset acquisition, which is expected to occur later this year. BioTime plans to use the proceeds from this financing to fund its planned $5 million cash investment in BAC. BioTime will advance funds to BAC to finance BACs continued progress in preparation for the completion of the stem cell asset acquisition transaction. Since Romulus … Continue reading →

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (ACT, OTCBB: ACTC or the Company), a leader in the field of regenerative medicine, today announced fourth quarter and year-end financial results for the period ended December 31, 2012. Highlights from the fourth quarter included: 2012 represented a transformative year for ACT both clinically and through favorable corporate developments, said Gary Rabin, chairman and CEO of ACT. The Company announced promising data from its most advanced clinical programs in AMD and SMD, and has made solid progress in bringing each of these programs through the clinical trials. ACT has also been able to remove many of the impediments to achieving a listing of its stock on a National Exchange, by eliminating significant contingent liabilities through resolution of outstanding litigation. We believe the Company is now well positioned to achieve both its clinical and corporate objectives in 2013. 2012 Fourth Quarter Financial Results Advanced Cell had revenue totaling $124,434 for the three months ended December 31, 2012 as compared to $66,238 in the same period in 2011. Research and Development expenses for the fourth quarter in 2012 and 2011 were $3.7 and $2.9 million respectively. The Company reported a loss from operations of $(6.2) … Continue reading →

Mar. 5, 2013 Researchers at the University of Minnesota's Lillehei Heart Institute have combined genetic repair with cellular reprogramming to generate stem cells capable of muscle regeneration in a mouse model for Duchenne Muscular Dystrophy (DMD). The research, which provides proof-of-principle for the feasibility of combining induced pluripotent stem cell technology and genetic correction to treat muscular dystrophy, could present a major step forward in autologous cell-based therapies for DMD and similar conditions and should pave the way for testing the approach in reprogrammed human pluripotent cells from muscular dystrophy patients. The research is published in Nature Communications. To achieve a meaningful, effective muscular dystrophy therapy in the mouse model, University of Minnesota researchers combined three groundbreaking technologies. First, researchers reprogrammed skin cells into "pluripotent" cells -- cells capable of differentiation into any of the mature cell types within an organism. The researchers generated pluripotent cells from the skin of mice that carry mutations in the dystrophin and utrophin genes, causing the mice to develop a severe case of muscular dystrophy, much like the type seen in human DMD patients. This provided a platform that would mimic what would theoretically occur in human models. The second technology employed is a … Continue reading →